JUN and Jeune syndrome: Recently, AP-1 was observed to have a role in fluoxetine response in a murine model of heightened anxiety (Chottekalapanda et al., 2020), and was also found to be activated by other factors such as BDNF, which is itself a factor influencing the response to different ATD treatments (Colle et al., 2015).